Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01597739 | A Study of JNJ-40346527 in Patients With Active Rheumatoid Arthritis Despite Disease-modifying Antirheumatic Drug Therapy | PHASE2 | COMPLETED | 96 | — | — | Jul 1, 2012 | Apr 1, 2013 | Apr 8, 2014 | 32 | Argentina, Bulgaria +8 |
The DAS28 is a statistically derived index combining tender joints (28 joints), swollen joints (28 joints), CRP, and an overall assessment of disease activity.
| Arm | Type | Description |
|---|---|---|
| JNJ-40346527 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| JNJ-40346527 | DRUG | Type=exact number; unit=mg; number=100, form=capsule; route=oral use; twice daily. |
| Placebo | DRUG | Form=capsule; route=oral use; twice daily. |
Inclusion Criteria: * Diagnosis of rheumatoid arthritis (RA) for at least 6 months prior to screening * Have been positive for, or are positive at screening for, either anti-cyclic citrullinated peptide (anti-CCP) antibody or rheumatoid factor (RF) in serum * Have active RA with at least 6 swollen ...